Strongbridge Biopharma plc - Ordinary Shares (SBBP) Company Bio
Strongbridge Biopharma PLC is focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. The company was founded in 1996 and is based in Trevose, Pennsylvania.
Strongbridge Biopharma (SBBP) has priced its public offering of ~11.1M ordinary shares at $2.25/share for total gross proceeds of ~$25M.Underwriters' over-allotment is an additional ~1.67M shares. Net proceeds will be used for development and commercialization of Recorlev in U.S., support the life cycle management activities of Keveyis and other general...
Strongbridge Biopharma plc, (SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that at the request of the Board of Directors, John H. Johnson has agreed to become the chief executive officer (CEO) of Strongbridge. Mr. Johnson, who has served as chairman of Strongbridge since March 2015, assumed the position of executive chairman in November 2019 to lead the organization while the Board conducted a formal search to identify a new CEO.